EMA to review Atara's MAA submission for allogeneic T-cell therapy: ‘A watershed moment for the field’
The EMA has validated Atara Biotherapeutics' Marketing Authorization Application (MAA) for tabelecleucel (tab-cel), the first time an off-the-shelf allogeneic T-cell therapy will be evaluated by any regulatory agency in the world.